SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
(4) - EconoTimes)
CAMBRIDGE, Mass., July 31, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, granted equity awards on July 31, 2017, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to six individuals hired by Sarepta in July 2017. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 15,320 shares of Sarepta's common stock. The options have an exercise price of $38.58 per share, which is equal to the closing price of Sarepta's common stock on July 31, 2017. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
